To assess whether this interaction occurred at the endogenous level, endogenous KRAS was immunoprecipitated from SW620 human KRAS-mutant cancer cells, chosen for their high endogenous KRAS expression, with an α-KRAS antibody, followed by immunoblot with an α-PIP5K1A antibody, which confirmed that PIP5K1A CO-IP with KRAS (Fig. 3d). This evidence concerns the gene KRAS and cancer.